← Eichor
Condition: Anaplastic Lymphoma Kinase Positive Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Anaplastic Lymphoma Kinase Positive

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL
Phase 2 · 1 location(s) · New York Medical College · NCT07013565Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib
Phase N/A · 1 location(s) · Centro de Tratamiento e Investigación sobre Cáncer, Luis Car · NCT07633626Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors
Phase 1/Phase 2 · 2 location(s) · Princess Maxima Center for Pediatric Oncology · NCT04925609Real-World Study of Iruplinalkib in the Treatment of ALK-Positive Non-Small Cell Lung Cancer
Phase N/A · 1 location(s) · Jinming Yu · NCT05991895Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
Phase 1 · 2 location(s) · Baylor College of Medicine · NCT06176690Longitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC (Galileo Project)
Phase N/A · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT06234579International Rare Histiocytic Disorders Registry (IRHDR)
Phase N/A · 15 location(s) · The Hospital for Sick Children · NCT02285582Neoadjuvant Therapy With Ensartinib Combined With Chemotherapy for ALK-positive Non - Small Cell Lung Cancer (NSCLC)
Phase 1/Phase 2 · 1 location(s) · Tang-Du Hospital · NCT07354061Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before C
Phase 2 · 7 location(s) · Mayo Clinic · NCT06834373A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
Phase 1/Phase 2 · 12 location(s) · TRIANA Biomedicines, Inc. · NCT07491497Gilteritinib for the Treatment of ALK NSCLC
Phase 1 · 3 location(s) · University of Michigan Rogel Cancer Center · NCT06225427A Registry for People With T-cell Lymphoma
Phase N/A · 26 location(s) · Memorial Sloan Kettering Cancer Center · NCT05978141Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC
Phase 2 · 1 location(s) · Guangdong Association of Clinical Trials · NCT06092086Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma
Phase 3 · 1 location(s) · Fudan University · NCT07300514Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib
Phase N/A · 1 location(s) · Peking University Shenzhen Hospital · NCT07374614A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
Phase 1 · 16 location(s) · Astellas Pharma Global Development, Inc. · NCT07140016Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Ther
Phase N/A · 44 location(s) · Hoffmann-La Roche · NCT06862869Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer
Phase 2 · 1 location(s) · Pingping Song · NCT05765877Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World C
NA · 31 location(s) · Pfizer · NCT06487078Patient-centered, Optimal Integration of Survivorship and Palliative Care
NA · 1 location(s) · Massachusetts General Hospital · NCT04900935Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC
NA · 46 location(s) · Groupe Francais De Pneumo-Cancerologie · NCT05122806Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients
Phase N/A · 1 location(s) · Sichuan Cancer Hospital and Research Institute · NCT06361589DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Canc
Phase 2/Phase 3 · 27 location(s) · Cancer Research UK · NCT05770037Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer
Phase 2 · 1 location(s) · Hebei Medical University Fourth Hospital · NCT05241028Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Phase 3 · 157 location(s) · Nuvalent Inc. · NCT06765109Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT07415005Alectinib Pharmacokinetic in Patients With NSCLC
Phase 1/Phase 2 · 1 location(s) · Instituto Nacional de Cancerologia de Mexico · NCT05713006A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (AL
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07001384A Real World Study of Ensartinib in Advanced ALK-positive NSCLC
Phase N/A · 1 location(s) · Peking Union Medical College Hospital · NCT05498064Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive La
Phase 1 · 1 location(s) · University of Washington · NCT04231877
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.